...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Resverlogix Announces Corporate Update Conference Call & Webcast on June 10, 2020 and Upcoming Presentation at the 57th ERA-EDTA Virtual Congress on
Reply New Message
Prev Message Back To Forum Threaded View Next Message

Actually it's only page 200 of the entire doc and it concludes the following :

3P-MACE + Hosp CHF, baseline eGFR <60 ml/min with a P-Value = 0.02.

"Conclusion: Patients with T2D, ACS, and Stage 3 CKD have a very high risk of subse-quent MACE plus CHF hospitalization. The BET protein inhibitor ABP may reduce this risk."

That's all I see.

Koo

 

1 Recommendations
Reply New Message
Prev Message Back To Forum Threaded View Next Message
Share
Share
New Message
Please login to post a reply